The ARRIVE trial evaluated elective labour induction at 39 weeks versus expectant management in low-risk nulliparous women. The primary finding was that induction at 39 weeks:
- A Significantly increased the cesarean delivery rate
- B Reduced the composite perinatal morbidity/mortality outcome
- C Did not increase the cesarean delivery rate and had similar perinatal outcomes ✓
- D Increased the rate of neonatal ICU admission
Correct answer: C. Did not increase the cesarean delivery rate and had similar perinatal outcomes
Explanation
The ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial (NEJM 2018) found that elective induction of labour at 39 weeks in low-risk nulliparous women did NOT increase the rate of cesarean delivery (18.6% vs 22.2%; P < 0.001) and was associated with lower rates of cesarean compared to expectant management. Perinatal outcomes were similar. This countered the traditional belief that elective induction increases cesarean rates.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.